Stay updated on Gantenerumab in Early Alzheimer's Disease Clinical Trial
Sign up to get notified when there's something new on the Gantenerumab in Early Alzheimer's Disease Clinical Trial page.

Latest updates to the Gantenerumab in Early Alzheimer's Disease Clinical Trial page
- Check6 days agoChange DetectedA site-wide notice about NIH’s transition from “Artificial Intelligence” to “Super Intelligence” appears above the error page, and the site revision identifier is updated.SummaryDifference1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check34 days agoChange DetectedThe page now displays a 403 Forbidden error for the study record instead of the usual content, indicating that access to the record is blocked.SummaryDifference18%

- Check41 days agoChange DetectedA new study location San Martin de Porres, Peru, 15102 was added and the San Martín de Porres entry was removed. The page revision was updated from v3.6.6 to v3.7.0.SummaryDifference0.0%

- Check55 days agoChange DetectedRevision tag updated from v3.6.5 to v3.6.6 on the page, indicating a small maintenance/template update. The change does not modify any study text, eligibility criteria, locations, or outcome data.SummaryDifference0.0%

- Check62 days agoChange DetectedA new NIH grant/contract reference (2017) was added, indicating funding information associated with the trial in the study’s identifiers.SummaryDifference0.0%

Stay in the know with updates to Gantenerumab in Early Alzheimer's Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gantenerumab in Early Alzheimer's Disease Clinical Trial page.